Yang, C H <br/><br/>
Bortezomib (VELCADE) in metastatic breast cancer: pharmacodynamics, biological effects, and prediction of clinical benefits.  [electronic resource] 

 -  Annals of oncology : official journal of the European Society for Medical Oncology  May 2006 
 - 813-7 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article 
<br/><br/><label>ISSN: </label>0923-7534 
<br/><br/><label>Standard No.: </label>10.1093/annonc/mdj131  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Bone Neoplasms--drug therapy<br/>Boronic Acids--pharmacology<br/>Bortezomib<br/>Breast Neoplasms--drug therapy<br/>Disease Progression<br/>Disease-Free Survival<br/>Female<br/>Humans<br/>Male<br/>Maximum Tolerated Dose<br/>Middle Aged<br/>Pleural Neoplasms--drug therapy<br/>Protease Inhibitors--pharmacology<br/>Pyrazines--pharmacology<br/>Receptors, Estrogen--metabolism<br/>Receptors, Progesterone--metabolism<br/>Soft Tissue Neoplasms--drug therapy<br/>Survival Rate<br/>Treatment Outcome